0000000000625602

AUTHOR

Jennifer J. Turner

0000-0001-5550-3375

showing 4 related works from this author

InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future dir…

2010

Abstract After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and “in situ” …

medicine.medical_specialtyPathologyLymphoid NeoplasiaLymphomabusiness.industryImmunologyMEDLINELymphoproliferative disordersCell BiologyHematologyComputational biologyWorld Health Organizationmedicine.diseaseBiochemistryWorld healthLymphomaEpidemiologic StudiesEpidemiologymedicineHumansLymphoid neoplasmsEpidemiologic researchbusinessWho classificationSocieties MedicalBlood
researchProduct

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

2018

Abstract A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of “heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL…

Male0301 basic medicineHeterozygoteCancer Researchmedicine.medical_specialtySUSCEPTIBILITY LOCIChronic lymphocytic leukemiaEPIDEMIOLOGIC RESEARCHGenome-wide association studyHuman leukocyte antigenBiologyCLASSIFICATIONANTIGENSArticleGenetic Heterogeneity03 medical and health sciencesimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineINTERLYMPHHumans1112 Oncology and CarcinogenesisOncology & CarcinogenesisProspective StudiesGENOME-WIDE ASSOCIATIONAlleleHLA ComplexScience & TechnologyHematologyCHRONIC LYMPHOCYTIC-LEUKEMIAGenetic heterogeneityLymphoma Non-HodgkinHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHETEROZYGOTE ADVANTAGEmedicine.disease3. Good healthLymphoma030104 developmental biologyOncologyCase-Control StudiesImmunologyB-VIRUS INFECTIONFemaleLife Sciences & BiomedicineNEOPLASMSGenome-Wide Association StudyCancer Research
researchProduct

Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci.

2015

Autoimmune conditions and immune system-related genetic variations are associated with risk of non-Hodgkin lymphoma (NHL). In a pooled analysis of 8,692 NHL cases and 9,260 controls from 14 studies (1988-2007) within the International Lymphoma Epidemiology Consortium, we evaluated the interaction between immune system genetic variants and autoimmune conditions in NHL risk. We evaluated the immunity-related single nucleotide polymorphisms rs1800629 (tumor necrosis factor gene (TNF) G308A), rs1800890 (interleukin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561 (HLA class II), and rs2647012 (HLA class II)) and categorized autoimmune conditions as prim…

LymphomaEpidemiologyOriginal Contributionstumor necrosis factorFollicular lymphomaNon-HodgkininteractionSingle-nucleotide polymorphismHuman leukocyte antigenmedicine.disease_causePolymorphism Single NucleotideAutoimmune DiseaseMedical and Health SciencesMathematical SciencesAutoimmunityAutoimmune DiseasesRare Diseasesimmune system diseasesHLA Antigenshuman leukocyte antigenhemic and lymphatic diseasesGenotypemedicineGeneticsHumans2.1 Biological and endogenous factorsPolymorphismAetiologyCancerbusiness.industryTumor Necrosis Factor-alphaLymphoma Non-HodgkinInflammatory and immune systemautoimmune conditionsOdds ratioSingle NucleotideHematologymedicine.diseaseAutoimmune conditions - risk of non-Hodgkin lymphoma (NHL)LymphomaInterleukin-10Case-Control StudiesImmunologyHIV/AIDSbusinessDiffuse large B-cell lymphomaenvironment
researchProduct

Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis

2009

AbstractWe performed a pooled analysis of data on atopic disease and risk of non–Hodgkin lymphoma (NHL) from 13 case-control studies, including 13,535 NHL cases and 16,388 controls. Self-reported atopic diseases diagnosed 2 years or more before NHL diagnosis (cases) or interview (controls) were analyzed. Pooled odds ratios (OR) and 95% confidence intervals (95% CI) were computed in two-stage random-effects or joint fixed-effects models, and adjusted for age, sex, and study center. When modeled individually, lifetime history of asthma, hay fever, specific allergy (excluding hay fever, asthma, and eczema), and food allergy were associated with a significant reduction in NHL risk, and there wa…

AdultMaleCancer Researchmedicine.medical_specialtyAllergyAdolescentCutaneous lymphomaArticleAtopyYoung AdultMeta-Analysis as Topicimmune system diseasesRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHypersensitivityHumansRisk factorAsthmaAgedAged 80 and overbusiness.industryLymphoma Non-HodgkinOdds ratioMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaOncologyCase-Control StudiesImmunologyHay feverFemalebusiness
researchProduct